Negative impact of pretreatment anemia on local control after neoadjuvant chemoradiotherapy and surgery for rectal cancer

Radiation Oncology Journal

Volumn 30, Issue 3, 2012, Pages 117-123

  Lee, Hyebin ^a   Park, Hee Chul ^a   Park, Won ^a   Choi, Doo Ho ^a   Kim, Young Il ^a   Park, Young Suk ^a   Park, Joon Oh ^a   Chun, Ho Kyung ^a   Lee, Woo Yong ^a   Kim, Hee Cheol ^a   Yun, Seong Hyeon ^a   Cho, Yong Beom ^a   Park, Yoon Ah ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Anemia; Concurrent chemoradiotherapy; Neoadjuvant therapy; Rectal cancer

Indexed keywords

EID: 84868333691     PISSN: 22341900     EISSN: 22343164     Source Type: Journal    
DOI: 10.3857/roj.2012.30.3.117     Document Type: Review

References (24)

1. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery-the clue to pelvic recurrence? Br J Surg 1982;69:613-6.
2. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986;1:1479-82.
3. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-46.
4. Peeters KC, Marijnen CA, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007;246:693-701.
5. Dunst J, Kuhnt T, Strauss HG, et al. Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 2003;56:778-87.
6. Fein DA, Lee WR, Hanlon AL, et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995; 13:2077-83.
7. Tanvetyanon T, Choudhury AM. Severity, risk factors, and physician practices in the management of anemia during concurrent chemoradiation for head and neck carcinoma. Cancer 2006;106:1554-9.
8. Pradier O, Lederer K, Hille A, et al. Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter. J Cancer Res Clin Oncol 2005;131:261-9.
9. MacRae R, Shyr Y, Johnson D, Choy H. Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. Radiother Oncol 2002;64:37-40.
10. Neuhof D, Neumayer F, Einbeck W, et al. Retrospective evaluation of combined modality treatment and prognostic factors in patients with esophageal cancer. Acta Oncol 2005;44:168-73.
11. Zenda S, Hironaka S, Boku N, et al. Impact of hemoglobin level on survival in definitive chemoradiotherapy for T4/M1 lymph node esophageal cancer. Dis Esophagus 2008;21:195-200.
12. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006;107:1747-50.
13. Harrison LB, Shasha D, Homel P. Prevalence of anemia in cancer patients undergoing radiotherapy: prognostic significance and treatment. Oncology 2002;63 Suppl 2:11-8.
14. Box B, Lindsey I, Wheeler JM, et al. Neoadjuvant therapy for rectal cancer: improved tumor response, local recurrence, and overall survival in nonanemic patients. Dis Colon Rectum 2005;48:1153-60.
15. Berardi R, Braconi C, Mantello G, et al. Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer. Ann Oncol 2006;17:1661-4.
16. Rades D, Kuhn H, Schultze J, et al. Prognostic factors affecting locally recurrent rectal cancer and clinical significance of hemoglobin. Int J Radiat Oncol Biol Phys 2008;70:1087-93.
17. Lee SD, Park JW, Park KS, et al. Influence of anemia on tumor response to preoperative chemoradiotherapy for locally advanced rectal cancer. Int J Colorectal Dis 2009;24:1451-8.
18. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B; Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74.
19. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997;34:4-12.
20. Park HC, Janjan NA, Mendoza TR, et al. Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2009;75:775-81.
21. Cella D, Bron D. The effect of Epoetin alfa on quality of life in anemic cancer patients. Cancer Pract 1999;7:177-82.
22. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010;28:4996-5010.
23. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
24. Hoskin PJ, Robinson M, Slevin N, Morgan D, Harrington K, Gaffney C. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer. J Clin Oncol 2009;27:5751-6.